CompletedPhase 1

Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy

United States17 participantsStarted 2021-08-06

Plain-language summary

This is a multicenter Phase 1b study evaluating the safety, tolerability, and preliminary anti-tumor activity of NT-I7 administration following standard of care CD19 CAR T-cell therapy for eligible subjects with r/r LBCL.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Subjects must have a life expectancy of greater than or equal to 12 weeks per assessment from the enrolling physician.
. Adequate organ and marrow function per institutional guidelines at the start of lymphodepleting chemotherapy as pre-conditioning for SOC CD19 CAR T-cell infusion.

Exclusion criteria

. Hemoglobin ≥8.0 g/dL or ≥4.96 mmol/L
. Absolute neutrophil count ≥1,000/µL
. Platelets \>50,000/µL
. Total bilirubin ≤1.5 × institutional upper limit of normal (ULN) OR direct bilirubin ≤ULN for subjects with total bilirubin levels \>1.5 × ULN, except subject with documented Gilbert's syndrome (\>3 x ULN), who must have a baseline total bilirubin ≤ 3.0 mg/dL

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

For Dose Escalation Phase: Incidence of adverse events (AE)

Timeframe: 21 Days

Incidence of Dose Limiting Toxicities (DLT)

Timeframe: 21 Days

To determine the Maximum Tolerated Dose (MTD)

Timeframe: 21 Days

To determine the Recommended Phase 2 Dose (RP2D)

Timeframe: 21 Days

Trial details

NCT IDNCT05075603

SponsorNeoImmuneTech

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2024-12-18

View on ClinicalTrials.gov More Refractory Diffuse Large B-cell Lymphoma trials

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Subjects must have a life expectancy of greater than or equal to 12 weeks per assessment from the enrolling physician.
. Adequate organ and marrow function per institutional guidelines at the start of lymphodepleting chemotherapy as pre-conditioning for SOC CD19 CAR T-cell infusion.

Exclusion criteria

. Hemoglobin ≥8.0 g/dL or ≥4.96 mmol/L
. Absolute neutrophil count ≥1,000/µL
. Platelets \>50,000/µL
. Total bilirubin ≤1.5 × institutional upper limit of normal (ULN) OR direct bilirubin ≤ULN for subjects with total bilirubin levels \>1.5 × ULN, except subject with documented Gilbert's syndrome (\>3 x ULN), who must have a baseline total bilirubin ≤ 3.0 mg/dL